Their critical role in development and –progression of cancer has led to introduction of MEK inhibitors as potential approach in cancer management.
Global MEK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Global & Regional Market Analysis
- Global MEK Inhibitors Market Opportunity Assessment: > USD 3 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 4 Drugs ( Trametinib, Binimetinib, Selumetinib, Cobimetinib)
- Approved MEK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
Download Report: https://www.kuickresearch.com/report-mek-map-kinase-inhibitor-market-size-clinical-trials-report
Tyrosine protein kinase inhibitors represent one of the promising drug classes for the management of various cancers. MEK (mitogen-activated protein kinase) are dual specificity Tyr/Thr protein kinase which has critical role in the in cell proliferation, differentiation, apoptosis, and stress responses. Their critical role in development and –progression of cancer has led to introduction of MEK inhibitors as potential approach in cancer management. Mekinist (Trametinib) developed by GlaxoSmithKline was the first MEK inhibitor approved by regulatory bodies in 2014. Later, three other MEK inhibitors including Cotellic, Mektovi and Koselugo also entered the market for the management of wide range of cancers.
The rapid anti-tumor observed associated with the use of MEK monotherapy were not long lasting owing to acquired resistance. To mitigate these challenges, researchers are not utilizing MEK inhibitors in combination therapy along with BRAF inhibitors, and other targeted therapies. For instance in June 2022, US FDA has granted approval to Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation. The rapid approval of the drug is due to encouraging response from phase-III clinical trial which has shown to enhance the outcomes in patients in comparison to monotherapy.
In addition to this, recent results from TAPUR study showed that the combination of cobimetinib (MEK inhibitor) plus vemurafenib demonstrated antitumor activity among patients with BRAF mutations who are not otherwise eligible for treatment with other FDA-approved therapies. 5The study showed that the disease control ate was 68% and overall survival rate was 15.2 months. Moreover, triple combination therapy of anti-PD-1/PD-L1 immunotherapy and anti-BRAF plus anti-MEK targeted therapy has also emerged as a promising antitumor strategy and is increasingly being used in clinical trials for the management of melanoma. Therefore, it is expected that combination therapy will dominate the global market during the forecast period.
Apart from approved therapeutic indications, several ongoing clinical trials are also evaluating the role of approved drugs in other therapeutic indications which will also drive the growth of market during the forecast period. For instance, recent clinical trial demonstrated that MEK inhibitor trametinib (Mekinist) reduced the risk of disease progression or death by 52% compared with current standard-of-care (SOC) therapies in patients with relapsed or persistent low-grade serous ovarian carcinoma, making it the potential new SOC for this patient population. Several other trials are evaluating the role of Koselugo in the management of various cancers including thyroid, breast, pancreatic, colorectal, or non-small cell lung cancer. It is expected that the drug will gain extended approval in other therapeutic conditions in coming years, which will further propel the growth of market.
The global MEK inhibitor market is highly consolidated and consists of several players including AstraZeneca, Bristol Meyer Squibb, Pfizer, Roche, Spring Work Therapeutics, and others. The rise in research activities by pharmaceutical gaints have led to the development of robust pipeline of MEK inhibitor drugs which is expected to enter the market during the forecast period. The potential candidates in the developmental pipeline are NFX-179, CS3006, HL085, Pimacertib and Mirdametinib. These drugs have shown encouraging response in clinical trials as monotherapy as well as combinational therapy and are mostly present in phase-I/II clinical trials.
As per our report findings, the global MEK inhibitor market is expected to surpass US$ 3 Billion by 2026. Various factors such as rising geriatric population associated with an increased risk of developing cancer, rising focus on research and development, and a large number of ongoing clinical trials are the major factors boosting the growth of the market. Further, favorable government policies for life science companies and government funding are also expected to boost the MEK inhibitor therapy demand in near future.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366